
Viridian Therapeutics VRDN
$ 14.47
3.65%
Annual report 2025
added 02-26-2026
Viridian Therapeutics P/E Ratio 2011-2026 | VRDN
Annual P/E Ratio Viridian Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.73 | -4.23 | -4.46 | -7.22 | -2.71 | -0.633 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.633 | -8.73 | -4.66 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
14.1 | $ 22.56 | 2.13 % | $ 3.74 B | ||
|
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | ||
|
argenx SE
ARGX
|
-33.7 | $ 785.07 | 2.57 % | $ 25 B | ||
|
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Akebia Therapeutics
AKBA
|
-62.5 | $ 1.43 | 3.62 % | $ 368 M | ||
|
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | ||
|
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
130 | $ 327.25 | 2.42 % | $ 42.9 B | ||
|
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
-4.52 | - | - | $ 8.42 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.9 | 3.7 % | $ 9.38 B | ||
|
Autolus Therapeutics plc
AUTL
|
-1.12 | $ 1.49 | 9.56 % | $ 397 M | ||
|
AVROBIO
AVRO
|
4.63 | - | 1083.1 % | $ 745 M | ||
|
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 20.4 | -0.87 % | $ 954 M | ||
|
Aquestive Therapeutics
AQST
|
-5.58 | $ 4.18 | 1.21 % | $ 447 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-1.16 | $ 2.66 | 3.5 % | $ 16.7 M | ||
|
AstraZeneca PLC
AZN
|
706 | - | - | $ 96.9 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-0.544 | - | -2.5 % | $ 5.88 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-213 | $ 24.61 | 5.76 % | $ 3.13 B | ||
|
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - | ||
|
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B | ||
|
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-0.859 | - | - | $ 231 M | ||
|
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | ||
|
Cabaletta Bio
CABA
|
-1.69 | $ 3.09 | 0.65 % | $ 310 M | ||
|
CymaBay Therapeutics
CBAY
|
-32.5 | - | - | $ 3.45 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | ||
|
Codiak BioSciences
CDAK
|
-6.45 | - | -55.98 % | $ 2.15 M | ||
|
Avid Bioservices
CDMO
|
-3.01 | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
-0.873 | - | - | $ 1.41 B | ||
|
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | ||
|
Checkpoint Therapeutics
CKPT
|
-2.85 | - | - | $ 169 M | ||
|
Celldex Therapeutics
CLDX
|
-7.88 | $ 32.41 | 3.38 % | $ 2.15 B | ||
|
Celsion Corporation
CLSN
|
-0.108 | - | -6.63 % | $ 13.9 M | ||
|
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | ||
|
Chimerix
CMRX
|
-1.26 | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
-1.29 | - | - | $ 401 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-467 | $ 3.88 | 2.11 % | $ 261 B |